Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Over the past year or so, Gilead Sciences has gone from Wall Street darling to a battleground stock. This sharp turn in investor sentiment has centered on the company's controversial and ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the August 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GILD ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the May 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its ...

That morning, the U.S. Food and Drug Administration (FDA) ordered a halt to Gilead's testing of a two-drug combination to treat human immunodeficiency viruses (HIV), the cause of acquired ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is under review by the Trump administration, and the Health and Human Services ...